Whew, having just finished the American Society of Hematology (ASH) meeting, we run on to the breast cancer symposium in San Antonio (SABCS), making for a very busy week of data deluge! Our Post ASH analysis will also run concurrently for a few days.
There are also a number of interesting areas to look out for in terms of interesting breast cancer developments.
Premium subscribers can find out more about the following below:
Companies: Roche, GSK, AbbVie, AstraZeneca, Novartis, Lilly
Drugs: Herceptin, Avastin, Perjeta, Tykerb, veliparib, olaparib, BKM120, ramucirumab, PD-1, PD-L1
Here’s a quick preview of some of the landmark data emerging from this conference, some positive, some negative.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.
Boston: Fallowing on from yesterday’s post about learnings from the AACR-NCI-EORTC conference in immuno-oncology, today’s post focuses on learnings from non-immune R&D, namely monoclonal antibodies and TKIs.
We know that cancer is a very complex topic and that adaptive resistance is increasingly a huge focus, but where are the new developments in this area and what can we learn from them in order to improve outcomes?
Another key area to consider is therapeutic index, that is are we shutting down enough of an oncogenic target’s activity in order to ensure efficacy? We’ve seen this in the anti-angiogenesis field, for example, where many VEGF inhibitors failed before bevacizumab (Avastin) finally cracked the nut in colorectal cancer and shifted the needle in terms of improving overall survival. We are now seeing this happen in other areas too, which will be covered below.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
This morning in Amsterdam brought some interesting breast and ovarian cancer presentations that I thought deserved a quick recap.
One is potentially practice changing in HER2 breast cancer and the other is a new product in development (Biomarin’s BMN 673) that is worth watching out for:
To learn more top line insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.